Go Pro
NASDAQ:BMRA

Biomerica (BMRA) Stock Price, News & Analysis

Biomerica logo
$1.56 -0.03 (-1.89%)
Closing price 07/30/2026 03:55 PM Eastern
Extended Trading
$1.52 -0.04 (-2.56%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Biomerica Stock (NASDAQ:BMRA)

Advanced

Key Stats

Today's Range
$1.52
$1.59
50-Day Range
$1.56
$2.49
52-Week Range
$1.52
$4.60
Volume
10,848 shs
Average Volume
6,233 shs
Market Capitalization
$4.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
Consensus Rating
Sell

Company Overview

Biomerica, Inc. is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.

Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring. The company also produces food safety test kits capable of detecting allergens and gluten residues in food products, serving the needs of food manufacturers and regulatory agencies. Its proprietary testing platforms are designed to deliver rapid, reliable results with user-friendly workflows suitable for both centralized and decentralized laboratory settings.

Founded in the late 1970s and headquartered in Irvine, California, Biomerica maintains a network of direct sales representatives in the United States as well as partnerships with distributors across Europe, Asia and Latin America. The company pursues regulatory clearances such as CE marking and FDA approvals to support its global market expansion. Biomerica’s manufacturing facilities are configured to meet quality standards including ISO 13485, enabling scalable production of diagnostic kits and reagents.

Biomerica is managed by a leadership team with experience in diagnostics research, regulatory affairs and commercial operations. The company continues to invest in product development and strategic collaborations aimed at broadening its assay pipeline and addressing unmet clinical needs. Through ongoing innovation and a focus on building international distribution channels, Biomerica seeks to strengthen its position in the growing in vitro diagnostics market.

AI Generated. May Contain Errors.

Biomerica Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
57th Percentile Overall Score

BMRA MarketRank™: 

Biomerica scored higher than 57% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Biomerica has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Biomerica has a consensus price target of $9.00, representing about 476.9% upside from its current price of $1.56.

  • Amount of Analyst Coverage

    Biomerica has only been the subject of 2 research reports in the past 90 days.

  • Read more about Biomerica's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Biomerica is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Biomerica is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Biomerica has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Biomerica's valuation and earnings.
  • Percentage of Shares Shorted

    0.87% of the float of Biomerica has been sold short.
  • Short Interest Ratio / Days to Cover

    Biomerica has a short interest ratio ("days to cover") of 3.15, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Biomerica has recently decreased by 32.36%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Biomerica does not currently pay a dividend.

  • Dividend Growth

    Biomerica does not have a long track record of dividend growth.

  • News Sentiment

    Biomerica has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Biomerica this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Biomerica insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    18.00% of the stock of Biomerica is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    22.28% of the stock of Biomerica is held by institutions.

  • Read more about Biomerica's insider trading history.
Receive BMRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomerica and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BMRA Stock News Headlines

Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
See More Headlines

BMRA Stock Analysis - Frequently Asked Questions

Biomerica's stock was trading at $2.52 at the beginning of 2026. Since then, BMRA stock has decreased by 38.1% and is now trading at $1.56.

Biomerica, Inc. (NASDAQ:BMRA) posted its quarterly earnings results on Monday, April, 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.76. The company had revenue of $0.99 million for the quarter, compared to analysts' expectations of $3.63 million. Biomerica had a negative trailing twelve-month return on equity of 98.14% and a negative net margin of 96.49%.

Biomerica shares reverse split on the morning of Monday, April 21st 2025.The 1-8 reverse split was announced on Wednesday, April 16th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 18th 2025. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

Shares of BMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Biomerica investors own include Pfizer (PFE), Gilead Sciences (GILD), AT&T (T), NIO (NIO), ExxonMobil (XOM), Avino Silver & Gold Mines (ASM) and Bristol Myers Squibb (BMY).

Company Calendar

Last Earnings
4/13/2026
Today
7/31/2026
Next Earnings (Estimated)
8/27/2026
Fiscal Year End
5/31/2027

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BMRA
CIK
73290
Employees
60
Year Founded
1971

Price Target and Rating

High Price Target
$9.00
Low Price Target
$9.00
Potential Upside/Downside
+476.9%
Consensus Rating
Sell
Rating Score (0-4)
1.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.89)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$4.97 million
Net Margins
-96.49%
Pretax Margin
-96.02%
Return on Equity
-98.14%
Return on Assets
-70.42%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.64
Quick Ratio
1.59

Sales & Book Value

Annual Sales
$5.31 million
Price / Sales
0.91
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.61 per share
Price / Book
0.97

Miscellaneous

Outstanding Shares
3,090,000
Free Float
2,534,000
Market Cap
$4.82 million
Optionable
No Data
Beta
0.33

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:BMRA) was last updated on 7/31/2026 by MarketBeat.com Staff.
From Our Partners